We specifically developed blood dendritic cell antigen 2 (BDCA2)-targeting CAR NK cells for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Here, CLEC4C is linked to CD4+/CD56+ hematodermic neoplasm.